NCT03217396
Biomarkers of Synaptic Damage in Multiple Sclerosis
Recruiting · Not specified · Neuromed IRCCS · registry updated 2022-10-28
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit. Subjects with other chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical reasons will be recruited As control groups.
Inclusion
- Male and female patients (age between 18 and 65 years)
- Diagnosis of MS in accordance with McDonald's (2010 rev) criteria,
- EDSS between 0 and 5.5 (included),
- Patients able to provide informed consent to participation in the study
Exclusion
- Inability to provide informed written consent
- Altered basal blood count
- Pregnancy or lactation
- Contraindications for the execution of magnetic resonance imaging with gadolinium
- Significant clinical conditions in addition to SM or other chronic neurodegenerative diseases including latent viral infections